Document Detail

Latent variable indirect response modeling of categorical endpoints representing change from baseline.
MedLine Citation:
PMID:  23275019     Owner:  NLM     Status:  Publisher    
Accurate exposure-response modeling is important in drug development. Methods are still evolving in the use of mechanistic, e.g., indirect response (IDR) models to relate discrete endpoints, mostly of the ordered categorical form, to placebo/co-medication effect and drug exposure. When the discrete endpoint is derived using change-from-baseline measurements, a mechanistic exposure-response modeling approach requires adjustment to maintain appropriate interpretation. This manuscript describes a new modeling method that integrates a latent-variable representation of IDR models with standard logistic regression. The new method also extends to general link functions that cover probit regression or continuous clinical endpoint modeling. Compared to an earlier latent variable approach that constrained the baseline probability of response to be 0, placebo effect parameters in the new model formulation are more readily interpretable and can be separately estimated from placebo data, thus allowing convenient and robust model estimation. A general inherent connection of some latent variable representations with baseline-normalized standard IDR models is derived. For describing clinical response endpoints, Type I and Type III IDR models are shown to be equivalent, therefore there are only three identifiable IDR models. This approach was applied to data from two phase III clinical trials of intravenously administered golimumab for the treatment of rheumatoid arthritis, where 20, 50, and 70 % improvement in the American College of Rheumatology disease severity criteria were used as efficacy endpoints. Likelihood profiling and visual predictive checks showed reasonable parameter estimation precision and model performance.
Chuanpu Hu; Zhenhua Xu; Alan M Mendelsohn; Honghui Zhou
Related Documents :
24425849 - Structure-function mapping: variability and conviction in tracing retinal nerve fibre b...
20730369 - Cross-cultural adaptation and evaluation of the psychometric properties of the falls ef...
23006079 - High-precision measurement of the ^{19}ne half-life and implications for right-handed w...
20556089 - Efficient electron beam pattern data format for the production of binary computer gener...
20699289 - Replication of urban innovations - prioritization of strategies for the replication of ...
24245679 - Cross nearest-spike interval based method to measure synchrony dynamics.
22061029 - Comparisons of the effect of electrical stimulation methods on postmortem ph decline in...
17076399 - Ground target recognition using rectangle estimation.
23445059 - An electromyogram-driven musculoskeletal model of the knee to predict in vivo joint con...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-30
Journal Detail:
Title:  Journal of pharmacokinetics and pharmacodynamics     Volume:  -     ISSN:  1573-8744     ISO Abbreviation:  J Pharmacokinet Pharmacodyn     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101096520     Medline TA:  J Pharmacokinet Pharmacodyn     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Pharmacokinetics and Pharmacometrics, Biologics Clinical Pharmacology, Janssen Research & Development, LLC, PO Box 776, 1400 McKean Road, Spring House, PA, 19477, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Variability and singularity arising from poor compliance in a pharmacokinetic model I: the multi-IV ...
Next Document:  Maternal and pregnancy-related death: causes and frequencies in an autopsy study population.